BIOMAT Database Logo BIOMAT Database Logo

Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells. 1991

H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
Department of Gastroenterological Surgery, Wakayama Medical College, Japan.

We investigated whether tumor cell lysis by lymphokine-activated killer (LAK) cells was enhanced by treatment of the tumor cells with cisplatin (CDDP) in vitro. Tumor cells were treated with CDDP in vitro, and the cytotoxic activity for LAK cells was measured by 4-h 51Cr-release assay. The alterations of succinate dehydrogenase (SD) activity, and DNA,RNA synthesis of tumor cells were analysed. The susceptibility of CDDP-treated (2 micrograms/ml, 2h) Daudi and KATO-III cells to lysis by short term-cultured LAK cells was enhanced, as was the susceptibility of CDDP-treated (2 micrograms/ml, 12h) autologous tumor and Daudi cells to lysis by long term-cultured LAK cells. SD activity and DNA synthesis in tumor cells were impaired by 12-h treatment with 2 micrograms/ml of CDDP, whereas those were not altered by 2-h treatment with 2 micrograms/ml of CDDP. The enhancement of the susceptibility of CDDP-treated tumor cells to long term-cultured LAK cells was thus elucidated; it was shown to be due to alterations of the tumor cells with regard to their SD activity and DNA synthesis. It is suggested that the combined therapy with CDDP and LAK cells offers hope for increasing the response rate and the long-term survival of cancer patients.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA
D013385 Succinate Dehydrogenase A flavoprotein containing oxidoreductase that catalyzes the dehydrogenation of SUCCINATE to fumarate. In most eukaryotic organisms this enzyme is a component of mitochondrial electron transport complex II. Succinic Oxidase,Fumarate Reductase,Succinic Dehydrogenase,Dehydrogenase, Succinate,Dehydrogenase, Succinic,Oxidase, Succinic,Reductase, Fumarate
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015979 Killer Cells, Lymphokine-Activated Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients. LAK Cells,Lymphokine-Activated Killer Cells,Cell, LAK,Cell, Lymphokine-Activated Killer,Cells, LAK,Cells, Lymphokine-Activated Killer,Killer Cell, Lymphokine-Activated,Killer Cells, Lymphokine Activated,LAK Cell,Lymphokine Activated Killer Cells,Lymphokine-Activated Killer Cell
D016219 Immunotherapy, Adoptive Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314) Adoptive Cellular Immunotherapy,Adoptive Immunotherapy,CAR T-Cell Therapy,Cellular Immunotherapy, Adoptive,Chimeric Antigen Receptor Therapy,Immunotherapy, Adoptive Cellular,Adoptive Cellular Immunotherapies,Adoptive Immunotherapies,CAR T Cell Therapy,CAR T-Cell Therapies,Cellular Immunotherapies, Adoptive,Immunotherapies, Adoptive,Immunotherapies, Adoptive Cellular,T-Cell Therapies, CAR,T-Cell Therapy, CAR,Therapies, CAR T-Cell,Therapy, CAR T-Cell

Related Publications

H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
Lymphokine activated killer cells.
October 1989, Blut,
H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
Antiproliferative cytokines secreted by lymphokine-activated killer cells stimulated with tumor cells.
September 1992, Journal of neurosurgery,
H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
May 1986, Journal of immunology (Baltimore, Md. : 1950),
H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
Lymphokine-activated killer cells are rejected in vivo by activated natural killer cells.
August 1991, Journal of immunology (Baltimore, Md. : 1950),
H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
Heat shock enhances the susceptibility of tumor cells to lysis by lymphokine-activated killer cells.
September 1995, Archives of otolaryngology--head & neck surgery,
H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
[Bronchial arterial infusion of lymphokine-activated killer cells stimulated by autologous tumor cells].
August 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
Immunotherapy of solid tumor by intratumoral infusion of lymphokine-activated killer cells.
August 1988, Japanese journal of cancer research : Gann,
H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
Lysis of fresh murine mammary tumor cells by syngeneic natural killer cells and lymphokine-activated killer cells.
January 1987, Cancer immunology, immunotherapy : CII,
H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
Autocytotoxic activity of lymphokine-activated killer cells: characterization of effector cells and susceptible targets.
January 1989, Anticancer research,
H Yamaue, and H Tanimura, and K Noguchi, and M Iwahashi, and T Tsunoda, and M Tani, and M Tamai, and T Hotta, and S Mizobata, and K Arii
Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
October 1986, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!